Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
16.68 USD | -2.66% | -2.54% | +52.84% |
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
May 18, 2022 at 06:53 am EDT
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. Its clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company's Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned, investigational, orally delivered, gut-restricted alpha 4 beta 7 (?4?7) specific integrin antagonist for inflammatory bowel disease (IBD).
Calendar
2023-11-06
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy

Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.13USD
Average target price
39.40USD
Spread / Average Target
+130.01%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+52.84% | 985 M $ | |
+115.74% | 70 M $ | |
+36.03% | 209 M $ | |
0.00% | 1 535 M $ | |
-54.24% | 53 M $ | |
-12.12% | 550 M $ | |
-39.18% | 712 M $ | |
+22.70% | 896 M $ | |
-29.59% | 290 M $ | |
-59.55% | 119 M $ |
- Markets
- Equities
- Stock Protagonist Therapeutics, Inc. - Nasdaq
- News
- Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating